In the fight against cancer, Yale has been at the forefront of understanding the fundamental mechanisms of cancer biology and in developing effective therapies for the treatment of cancer. Yale Cancer Center harnesses the resources of the Yale School of Medicine and Smilow Cancer Hospital to advance cancer research, prevention, and patient care, as well as community outreach and education.
There is a long history of excellence in cancer research at Yale University. Yale School of Medicine is home to the country's first university-based Medical Oncology section, and its faculty pioneered many breakthroughs in cancer treatments, including the first successful use of chemotherapy in 1942. Since then, our faculty has developed and characterized a number of therapeutic agents that are still in use today.
Yale Cancer Center's research efforts are spearheaded by Daniel DiMaio, MD, PhD, the Waldemar Von Zedtwitz Professor and Chairman of Genetics at Yale School of Medicine and Deputy Director of the Center. Through the six multispecialty research programs and seven shared resource facilities at Yale Cancer Center, our mission is to continually build on our knowledge of basic and translational cancer research and to push for accelerated progress for novel therapies.